Last update 26 Jun 2024

Oxybutynin Chloride

Last update 26 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryOxybutynin, marketed as DITROPAN®, is a medication approved by the US FDA in 1975 for the treatment of overactive bladder. Developed by Janssen, the drug works as an antagonist of acetylcholine at postganglionic muscarinic receptors, causing relaxation of the smooth muscle in the bladder. It is a racemic mixture of R- and S-isomers, with the antimuscarinic activity mainly residing in the Risomer. Additionally, the active metabolite, N-desethyloxybutynin, has similar pharmacological effects on human detrusor muscle as oxybutynin, as observed in in vitro studies. Overall, Oxybutynin Chloride offers relief to those experiencing urinary urgency, frequency, and incontinence.

Drug Type

Small molecule drug

Synonyms

oxybutynin, Oxybutynin (USAN/INN), Oxybutynin chloride (USP)

+ [37]

Target

mAChRs

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Skin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication

Hyperhidrosis Palmaris Et PlantarisUrinary Incontinence, UrgeUrinary Bladder, Overactive+ [3]

Inactive Indication

Lower Urinary Tract SymptomsSpinal Dysraphism

Originator Organization

Johnson & Johnson

Active Organization

Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd.

Hisamitsu Pharmaceutical Co., Inc.Teva Pharmaceuticals Europe BV

+ [4]

Inactive Organization

ALZA Corp.

Ortho-McNeil Pharmaceutical LLC

Janssen Pharmaceuticals, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (16 Jul 1975),

Urinary Bladder, Overactive

Regulation-

Structure

Molecular FormulaC22H32ClNO3

InChIKeySWIJYDAEGSIQPZ-UHFFFAOYSA-N

CAS Registry1508-65-2

100

Clinical Trials associated with Oxybutynin Chloride

NCT06106529 / Not yet recruitingPhase 3

A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer.

The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer.
The objectives it aims to answer are:
To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer
To assess side effects of oxybutynin versus venlafaxine.
To assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes.
To assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer.
Participants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total.
Researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.

Start Date15 Jun 2024

Sponsor / Collaborator

Stichting Reinier de Graaf Groep

NL-OMON56571 / RecruitingNot Applicable

An open label study to explore the feasibility and tolerability of 28 days use of intravaginal oxybutynin via the MedRing OAB system in out-patients with overactive bladder - Feasibility and tolerability of 28 days oxybutynin via the MedRing

Start Date26 Feb 2024

Sponsor / Collaborator-

NCT06049797 / RecruitingNot Applicable

A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms

Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from their HCP for up to 1 year. This real-world study will provide information on outcomes from various non-hormonal therapies. The study sponsor (Astellas) will not decide which therapy the women receive. However, the sponsor will provide instructions on when the women visit their clinic, and what is recorded during the study. Some of the visits will be in-person, but most will be virtual. The virtual visits can be carried out at home using a smartphone, tablet or computer. The main aim of the study is to check if the hot flashes and night sweats that bother women change after 12 weeks (3 months) of treatment. The study will also check the women's sleep patterns, their productivity at work, and their general well-being before and after starting treatment. The overall safety of the non-hormonal therapies will also be examined.

Start Date15 Nov 2023

Sponsor / Collaborator

Astellas Pharma Global Development, Inc.

100 Clinical Results associated with Oxybutynin Chloride

100 Translational Medicine associated with Oxybutynin Chloride

100 Patents (Medical) associated with Oxybutynin Chloride

1,514

Literatures (Medical) associated with Oxybutynin Chloride

05 Jul 2106·Oncotarget

Reactive oxygen species formation and bystander effects in gradient irradiation on human breast cancer cells

Article

Author: Rong, Yi ; Wu, Shiyong ; He, Feng ; Zuo, Li ; Zhou, Tingyang ; Lee, Shin Hee ; Zhang, Dongqing

Ionizing radiation (IR) in cancer radiotherapy can induce damage to neighboring cells via non-targeted effects by irradiated cells. These so-called bystander effects remain an area of interest as it may provide enhanced efficacy in killing carcinomas with minimal radiation. It is well known that reactive oxygen species (ROS) are ubiquitous among most biological activities. However, the role of ROS in bystander effects has not been thoroughly elucidated. We hypothesized that gradient irradiation (GI) has enhanced therapeutic effects via the ROS-mediated bystander pathways as compared to uniform irradiation (UI). We evaluated ROS generation, viability, and apoptosis in breast cancer cells (MCF-7) exposed to UI (5 Gy) or GI (8-2 Gy) in radiation fields at 2, 24 and 48 h after IR. We found that extracellular ROS release induced by GI was higher than that by UI at both 24 h (p < 0.001) and 48 h (p < 0.001). More apoptosis and less viability were observed in GI when compared to UI at either 24 h or 48 h after irradiation. The mean effective doses (ED) of GI were ~130% (24 h) and ~48% (48 h) higher than that of UI, respectively. Our results suggest that GI is superior to UI regarding redox mechanisms, ED, and toxic dosage to surrounding tissues.

01 Jan 2024·Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Severe night sweating treated by oxybutynin

Author: Dias, Leonor ; Martinot, Celine ; Arnulf, Isabelle ; Vaillant, Garance

CITATION:

Dias L, Martinot C, Vaillant G, Arnulf I. Severe night sweating treated by oxybutynin. J Clin Sleep Med. 2024;20(1):169-172.

01 Jan 2024·Urology

Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities

Article

Author: Escobar, Christina M ; Dusetzina, Stacie B ; Shapiro, Katherine ; Brucker, Benjamin M

OBJECTIVE:

To report out-of-pocket costs associated with overactive bladder (OAB) medications among Medicare beneficiaries and the uninsured.

METHODS:

We performed a cross-sectional analysis of the Centers for Medicare & Medicaid Services Prescription Drug Plan Formulary Data (Q1-2022). FDA-approved medications for OAB were identified. We calculated out-of-pocket costs for Medicare beneficiaries in each Part D prescription benefit phase, average retail price, total yearly costs and discounted prices through cash-pay discount coupons (GoodRx) or online pharmacies like Mark Cuban Cost Plus Drug Company (MCCPDC). We also report plan utilization management requirements.

RESULTS:

We analyzed 5721 plan formularies for 18 medications. Mirabegron was the only beta-3 agonist (B3). Only Vesicare oral solution (14.3% of plans) and Mirabegron (0.1%) required prior authorization. Many plans required step therapy for selective generic anticholinergics (ACH) (12.4%-43.3%), while the B3 rarely required step therapy (0.6%). Monthly costs varied by coverage phase and averaged $59 for ACHs in the initial coverage phase ($14 in catastrophic; $72 in coverage gap). The monthly cost for the B3 averaged $47 in the initial coverage phase ($26 in catastrophic; $129 in coverage gap). The total yearly cost for generic ACHs ranged from $494 (oxybutynin IR) to $1452 (darifenacin) and the yearly cost for brand-name ACHs ranged from $1175 (Toviaz ER) to $2198 (Oxytrol). The total yearly cost for the B3 was $1283.

CONCLUSION:

We evaluated coverage, out-of-pocket costs, total yearly costs, and utilization management for OAB medications to make pricing more transparent. While selective medications may be "covered," coverage does not translate into affordable drug prices.

News (Medical) associated with Oxybutynin Chloride

15 Jan 2024

·www.sciencedaily.com

New catalytic technique creates key component of incontinence drug in less time

Researchers have developed a unique catalyst that promises to revolutionize drug synthesis. It overcomes a common problem associated with the production of drugs from ketones. Using their catalyst, the researchers synthesized a key component of the commonly used incontinence drug oxybutynin. Their results underscore the potential of the catalyst to improve drug discovery and development. A research group at Nagoya University in Japan has developed a new catalyst that promises to revolutionize the asymmetric synthesis of pharmaceuticals called chiral macrocyclic dilithium(I) salt. It overcomes the lack of reactivity of ketones and the difficulty inducing them to arrange atoms, which are common challenges in drug-making. The researchers used their technique to synthesize a key intermediate of the incontinence drug oxybutynin. Their catalyst promises to contribute to future drug discovery and development. They published their results in the Journal of the American Chemical Society. "This research represents a major advance in chiral drug synthesis," said Professor Ishihara from Nagoya University. "Our catalyst can facilitate the rapid synthesis of complex compounds. This holds great promise for future drug discovery efforts." All drugs are made from precursor chemicals. Ideal precursors are versatile compounds that can create a wide variety of end products. One particularly versatile precursor is optically active tertiary propargyl alcohol. It is used to create pharmaceuticals, including anticancer agents, antibiotics, and antivirals. However, production of these important chemicals is hindered by the low reactivity of ketones, which are precursors of tertiary propargyl alcohols. In addition, there is the difficulty of their asymmetric induction, a process that favors the creation of a specific arrangement of atoms that is more suitable than other arrangements for making the drug. To overcome the low reactivity of the ketones, highly reactive lithium-based reactants, called lithium acetylides, are added. However, their reactivity is often insufficient for use with ketones. The development of a new catalyst was needed to promote the reaction and control the selection of the optimal arrangement of atoms. Enzymes are ideal for these reactions, as they lower the energy required to make the reaction occur. However, due to their large and complicated structure, the synthesis of enzymes is difficult. The currently used acyclic dilithium catalyst-based approach was pioneered by Kumamoto University's Makoto Nakajima. However, this approach has a limited substrate scope due to the self-aggregation of catalysts and an overly long reaction time of up to 12 hours. This creates a bottleneck when producing the desired drug. Professor Kazuaki Ishihara and his collaborators, which included his graduate students, developed a chiral macrocyclic dilithium(I) salt. It is a simple catalyst that functions like an enzyme, overcoming the decrease in reactivity by activating less reactive ketones. This allows the addition of acetylides, such as lithium acetylides. The large macrocyclic structure of the catalyst allows them to catalyze even bulky ketones. This prevents aggregation between the catalyst and the lithium-based reactants. Despite being simpler than enzymes, the researchers found that their catalyst was more efficient than other known catalysts. They successfully synthesized optically active tertiary propargyl alcohol from a variety of ketones. Although this industrial alcohol is difficult to produce by conventional methods, they synthesized it in 5 to 30 minutes. This is much faster than the 12 hours that Nakajima's catalyst-based production process takes. The addition of alkynyls to carbonyl compounds, such as ketones, is a valuable synthetic method for the preparation of versatile chiral alcohols that are widely found in pharmaceuticals and natural products. This research is a breakthrough in modern synthetic organic chemistry and a promising leap forward in drug discovery.

05 Dec 2022

·www.businesswire.com

$4.2 Billion Overactive Bladder Treatment (OAB) Markets - Global Forecasts to 2027: Growing R&D Investments and the Launch of Novel Therapies in the Coming Years - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering. The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have a significant positive impact. The adoption of novel treatments and the launch of new drugs for OAB treatment are also likely to support market growth in the coming years. Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021. Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market. The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period. Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment. North America held dominant share in 2021. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America. Competitive landscape The prominent players in this market are Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), and Endo Pharmaceuticals Inc. (Ireland). Market Dynamics Market Drivers Rising Prevalence of Overactive Bladder Syndrome Rapidly Aging Population and Subsequent Rise in Incidence of Diseases Characterized by Oab Development and Use of Innovative Intravesical Therapies Growing R&D Investments and the Launch of Novel Therapies in the Coming Years Market Restraints Frequent Product Recalls Increased Side-Effects of Anticholinergic Drugs Market Opportunities Novel Treatments, Robust Pipelines, and Patent Cliff of Certain Drugs Market Challenges Social Stigma and Lack of Awareness About OAB Companies mentioned: Abbvie Inc Ajanta Pharma Altherx Pharmaceuticals Amneal Pharmaceuticals LLC Apotex Inc Astellas Pharma Inc Bayer Ag Endo Pharmaceuticals Inc Glenmark Granules India Limited Hisamitsu Pharmaceutical Co Inc Hugel, Inc Intas Pharmaceuticals Ltd Johnson & Johnson Services, Inc Laborie Lupin Macleods Pharmaceuticals Ltd Medtronic Medytox Pfizer Inc Sun Pharmaceutical Industries Ltd Taiho Pharmaceutical Co Ltd Teva Pharmaceutical Industries Ltd Urovant Sciences Viatris Inc For more information about this report visit https://www.researchandmarkets.com/r/2n1a4y About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

09 Nov 2022

·www.prnewswire.com

Bromhidrosis Disease Treatment Market Size to Grow by 362.76 Mn, Increasing Number of M&A by Vendors to be a Key Trend - Technavio

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- The bromhidrosis disease treatment market size is expected to grow by USD 362.76 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 8.92% during the forecast period, according to Technavio. The market has been segmented by type geography (North America, Europe, Asia, and Rest of World (ROW) and (apocrine body odor and eccrine body odor). Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format Continue Reading Technavio has announced its latest market research report titled Global Bromhidrosis Disease Treatment Market 2022-2026 The rise in the number of patients affected by diabetes and kidney diseases, government awareness programs about the disease, and an increase in healthcare affordability in the US are some of the major factors propelling the market growth. However, factors such as the high cost of treatment, rise in the cost of R&D activities, and lack of knowledge of the disease will hamper the market growth. More details: Bromhidrosis Disease Treatment Market: Trend The increasing M&As is a key trend shaping the bromhidrosis disease treatment market. The key vendors are acquiring small vendors to gain access to new products and technologies at low costs. For instance, in February 2022, Ipsen Pharma partnered with Mayoly Spindler to sell its global consumer healthcare business. In May 2022, Pfizer Inc. announced the acquisition of Biohaven Pharmaceutical Holding Company Ltd. In January 2022, Novartis AG partnered with Alnylam to work on targeted therapy to restore liver function. Thus, the rise in the number of M&A will support the growth of the market in the coming years. Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. Buy Now for detailed information about market dynamics Bromhidrosis Disease Treatment Market: Type Landscape By type, the apocrine body odor segment will be a significant contributor to market growth during the forecast period. Apocrine sweat, when discharged, is colorless and odorless. In apocrine bromhidrosis, body odor is caused due to the combination of lipid-rich apocrine gland perspiration with microorganisms on the skin. This leads to the formation of thioalcohol. Thus, the increase in the number of people with apocrine bromhidrosis will drive the growth of the segment during the forecast period. Bromhidrosis Disease Treatment Market: Geographic Landscape By geography, North America is going to have lucrative growth during the forecast period. About 38% of the market's overall growth is expected to originate from the region. The US and Canada are the key markets for bromhidrosis disease treatment in North America. The growth of the market in the region is attributed to factors such as rising healthcare expenditures, a well-developed healthcare sector, a large patient population, and government backing for R&D. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report Bromhidrosis Disease Treatment Market: Companies Covered AbbVie Inc. - The company offers bromhidrosis disease treatment, namely Botox. Galderma SA - The company offers bromhidrosis disease treatment, namely Alluzience. Hikma Pharmaceuticals Plc - The company offers bromhidrosis disease treatment, namely Glycopyrrolate injection. Ipsen Pharma - The company offers bromhidrosis disease treatment, namely Dysport. Biovencer Healthcare Pvt. Ltd. Johnson & Johnson - The company offers bromhidrosis disease treatment, namely Ditropan XL, through its subsidiary Janssen. Boehringer Ingelheim International GmbH Journey Medical Corp. Medytox Inc. Merz Pharma GmbH & Co. KGaA Novartis AG Pfizer Inc. Bromhidrosis Disease Treatment Market: What our reports offer Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers market data from 2021 to 2026 Market trends (threats, challenges, drivers, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping recording the key common trends Company profiling with financials, detailed strategies, and recent developments Supply chain trends mapping the latest technological advancements Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000 Related Reports Gastrointestinal Diseases Therapeutics Market by Drug Class and Geography - Forecast and Analysis 2022-2026: The increasing incidence of gastrointestinal diseases is driving market growth. Gastrointestinal diseases have increased significantly across the globe. Improper diet, inactive lifestyle, stress, food sensitivity, and bacterial or viral infection are the major factors contributing to the increasing incidence of chronic and acute gastrointestinal diseases. Celiac Diseases Drugs Market by Therapy Type and Geography - Forecast and Analysis 2022-2026: Higher consumption of gluten-containing food is driving the market growth. Celiac disease is characterized by an increase in gluten deposition in the body due to the high consumption of food containing gluten. Pizza, cake, soups, beer, bread, cookies, pasta, and burgers are some of the widely consumed food that contains gluten. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Apocrine body odor - Market size and forecast 2021-2026 Exhibit 28: Chart on Apocrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Apocrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Apocrine body odor - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Apocrine body odor - Year-over-year growth 2021-2026 (%) 5.4 Eccrine body odor - Market size and forecast 2021-2026 Exhibit 32: Chart on Eccrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Eccrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Eccrine body odor - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Eccrine body odor - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Canada - Market size and forecast 2021-2026 Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.9 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.10 China - Market size and forecast 2021-2026 Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%) 7.11 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 AbbVie Inc. Exhibit 85: AbbVie Inc. - Overview Exhibit 86: AbbVie Inc. - Product / Service Exhibit 87: AbbVie Inc. - Key offerings 10.4 Boehringer Ingelheim International GmbH Exhibit 88: Boehringer Ingelheim International GmbH - Overview Exhibit 89: Boehringer Ingelheim International GmbH - Business segments Exhibit 90: Boehringer Ingelheim International GmbH - Key news Exhibit 91: Boehringer Ingelheim International GmbH - Key offerings Exhibit 92: Boehringer Ingelheim International GmbH - Segment focus 10.5 Galderma SA Exhibit 93: Galderma SA - Overview Exhibit 94: Galderma SA - Product / Service Exhibit 95: Galderma SA - Key news Exhibit 96: Galderma SA - Key offerings 10.6 Hikma Pharmaceuticals Plc Exhibit 97: Hikma Pharmaceuticals Plc - Overview Exhibit 98: Hikma Pharmaceuticals Plc - Business segments Exhibit 99: Hikma Pharmaceuticals Plc - Key offerings Exhibit 100: Hikma Pharmaceuticals Plc - Segment focus 10.7 Ipsen Pharma Exhibit 101: Ipsen Pharma - Overview Exhibit 102: Ipsen Pharma - Business segments Exhibit 103: Ipsen Pharma - Key offerings Exhibit 104: Ipsen Pharma - Segment focus 10.8 Johnson and Johnson Exhibit 105: Johnson and Johnson - Overview Exhibit 106: Johnson and Johnson - Business segments Exhibit 107: Johnson and Johnson - Key news Exhibit 108: Johnson and Johnson - Key offerings Exhibit 109: Johnson and Johnson - Segment focus 10.9 Medytox Inc. Exhibit 110: Medytox Inc. - Overview Exhibit 111: Medytox Inc. - Product / Service Exhibit 112: Medytox Inc. - Key offerings 10.10 Merz Pharma GmbH and Co. KGaA Exhibit 113: Merz Pharma GmbH and Co. KGaA - Overview Exhibit 114: Merz Pharma GmbH and Co. KGaA - Product / Service Exhibit 115: Merz Pharma GmbH and Co. KGaA - Key offerings 10.11 Novartis AG Exhibit 116: Novartis AG - Overview Exhibit 117: Novartis AG - Business segments Exhibit 118: Novartis AG - Key offerings Exhibit 119: Novartis AG - Segment focus 10.12 Pfizer Inc. Exhibit 120: Pfizer Inc. - Overview Exhibit 121: Pfizer Inc. - Product / Service Exhibit 122: Pfizer Inc. - Key news Exhibit 123: Pfizer Inc. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 124: Inclusions checklist Exhibit 125: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 126: Currency conversion rates for US$ 11.4 Research methodology Exhibit 127: Research methodology Exhibit 128: Validation techniques employed for market sizing Exhibit 129: Information sources 11.5 List of abbreviations Exhibit 130: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

AcquisitionCollaborate

100 Deals associated with Oxybutynin Chloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00722	Oxybutynin Chloride	G04BD04	DB01062

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperhidrosis Palmaris Et Plantaris	JP	Hisamitsu Pharmaceutical Co., Inc.	27 Mar 2013
Pollakisuria	JP	Clinigen KK	29 Mar 1988
Urinary Incontinence	JP	Clinigen KK	29 Mar 1988
Urinary urgency	JP	Clinigen KK	29 Mar 1988
Spinal Dysraphism	US	Ortho-McNeil Pharmaceutical LLC	29 Nov 1979
Urinary Incontinence, Urge	US	Ortho-McNeil Pharmaceutical LLC	29 Nov 1979
Urinary Bladder, Overactive	US	Janssen Pharmaceuticals, Inc.	16 Jul 1975

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lower Urinary Tract Symptoms	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	01 May 2004
Urination Disorders	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	01 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04090190 (CTgov)	Phase 4	Urinary Incontinence \| Urinary urgency \| Inflammation	20	Oxybutynin+Tolterodine+Trospium+Solifenacin+Fesoterodine	wykgyzektg(ylpaaalwsf) = mcxfqatgwn yzxtwfltew (zlbajsgnoe, qqkdphhcyl - yheujrmkqn) View more	-	03 Oct 2022
ERS2022	Not Applicable	Sleep Apnea, Obstructive	15	5 mg of Oxybutynin and 6 mg of Reboxetine (oxy-reb)	rgkchvdfhb(erjkdevmuj) = afhmtxdzky kxdbaqpzul (caxfqarnpa, 22.7 - 52.3)	-	04 Sep 2022
ERS2022	Not Applicable	Sleep Apnea, Obstructive	15	Placebo	rgkchvdfhb(erjkdevmuj) = cstfmvlrzy kxdbaqpzul (caxfqarnpa, 23.3 - 44.1)	-	04 Sep 2022
NCT04534491 (CTgov)	Phase 3	Urinary Bladder, Overactive	855	Oxybutynin	fsbkpokwfz(fmjhuejman) = cxqpcrjebl lsvsuhjrxm (elewhdglkt, vpfzzirmxp - cvepzrqahb) View more	-	20 Oct 2020
NCT02961790 (CTgov)	Phase 3	Hot Flashes \| Noninfiltrating Intraductal Carcinoma \| Invasive Mammary Carcinoma	150	Oxybutynin Chloride (High-dose Oxybutynin Chloride Group)	kdqdicqija(isdzcxlbqg) = uqtdicikib bofqolytcp (gjdwfvfqip, ouqwfgxvjj - nmmkwlvmfm) View more	-	03 Jun 2019
NCT02961790 (CTgov)	Phase 3		150	Oxybutynin Chloride (Low-dose Oxybutynin Chloride Group)	kdqdicqija(isdzcxlbqg) = hkgwwctasm bofqolytcp (gjdwfvfqip, vfxfglqdzn - vztjnwypnm) View more	-	03 Jun 2019
NCT02633371 (CTgov)	Not Applicable	Primary Axilary Hyperhidrosis	10	Oxybutynin 3% gel	jbvnztvbqe(dckpdaxizq) = nmefzmowwd aezfjkglvl (lkeuutoywa, oubfvdapao - ahhgltmcmn) View more	-	19 Jun 2018
NCT02176642 (CTgov)	Phase 4	Urinary urgency \| Urinary Incontinence, Urge	55	Posterior Tibial Nerve Stimulation+Oxybutynin extended release (Oxybutynin Plus PTNS)	xtjtujzzdf(rwmuvvjssf) = yugxygkbgm wqcsjsdoql (vutzxjizhk, qgmlzmpmtr - vmzfobqnto) View more	-	23 Jan 2018
NCT02176642 (CTgov)	Phase 4	Urinary urgency \| Urinary Incontinence, Urge	55	Posterior Tibial Nerve Stimulation (Placebo Plus PTNS)	xtjtujzzdf(rwmuvvjssf) = wfutxdaiec wqcsjsdoql (vutzxjizhk, pwyapvrrsr - etyuxwqjye) View more	-	23 Jan 2018
NCT03952299 (Pubmed \| J Pediatr Urol)	Phase 3	Urinary Bladder, Overactive	35	Transdermal oxybutynin patch (TOP)	isnldivufs(fffgfsapxv) = The main side effect was skin irritation at TOP site (35%), leading to discontinuation in 20% hwdzjsspbh (fxesthfjxr )	-	01 Aug 2014
NCT00223821 (CTgov)	Not Applicable	Urinary Incontinence, Urge	166	Behavior Training+Oxybutynin chloride, extended-release, individually-titrated	hmjcamuyqm(tmxtibwygz) = nomdixyajy niktfegwbi (tgxyqxgolk, znnrmaswvk - irjwrntzgy) View more	-	19 Dec 2013
NCT00613327 (CTgov)	Phase 4	Urinary Bladder, Overactive	345	Oxybutynin chloride OROS	elapffdvxy(xojfrlzijm) = rffcfpsnga tujqrgzmhj (cnnubalsrh, nyudopxefg - kiiokswmcd) View more	-	16 Sep 2013
NCT01796548 (RONDO, CTgov)	Phase 4	Neurogenic detrusor overactivity \| Urinary Bladder, Overactive	17	extended release (ER) oxybutynin chloride	cxfkxchibt(okcssykbjw) = xqxngqkfgd vvvafoanxo (qkrnpohvsl, mgkhndjeoi - wtieoudvjw) View more	-	31 Jul 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis